Goldman Sachs Conviction Buy List
Goldman's Sachs' (NYSE: GS) Conviction Buy List is a listing of stocks the investment bank's research team expects to outperform.
Goldman's Sachs' regional Conviction Buy and Sell lists represent investment recommendations focused on either the size of the potential return or the likelihood of the realization of the return. (from goldmansachs.com)
SI Note: This page will track StreetInsider.com reports that mention the Goldman Sachs Conviction Buy List. It is not a complete representation of the firm's list.
To get real time e-mail alerts on Conviction Buy List news sign-up here.
Anika Therapeutics, Inc. (Nasdaq: ANIK) 44% HIGHER; announced that it has received Health Canada approval for MONOVISC(TM), its single injection viscosupplement approved for the treatment of osteoarthritis of the knee. Anika expects to launch MONOVISC this month through its long-term ORTHOVISC(R) distribution partner in Canada, Rivex Pharma Inc., the specialty drug distribution division of Aurora, Ontario-based Helix BioPharma Corp. MONOVISC has been broadly available in the European Union since the second quarter of 2008.
AIG (NYSE: AIG) 25.4% HIGHER; jumping on reports that the new CEO said that he expects the company to be able to payback the U.S. government. In an interview, CEO Robert Benmosche said, "At the end of the day, we believe we will be able to pay back the government and we hope we will be able to do something for our shareholders as well." Click here to see the full report.
Reddy Ice ...
AVI BioPharma, Inc. (NASDAQ: AVII) 25.3% LOWER; announced that it intends to offer shares of its common stock and warrants to purchase shares of its common stock in a public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed.
Helicos BioSciences Corporation (NASDAQ: HLCS) 25% HIGHER; today announced the placement of a Helicos(TM) Genetic Analysis System at the Ontario Institute for Cancer Research with Drs. Tom Hudson and John McPherson.
Orsus Xelent Technologies, Inc. (Amex: ORS) 23.3% HIGHER; reports Q2 EPS of $0.08, compared to $0.05 in the same quarter last year. Revenue for the quarter was $23.3 million, versus $23.33 million in Q208.
The Bon-Ton Stores, Inc. (NASDAQ: BONT) 17.3% HIGHER; reports a Q2 loss of $2.04 vs. consensus for $2.24 loss - may not be comparable. Revenues were $609.2 million ...
